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AbstrACt
Objectives Given the novelty of proprotein convertase 
subtilisin-kexin type 9 inhibitors (PCSK9i), little is known 
regarding overall implementation or clinical characteristics 
among patients who initiate treatment. We aimed to 
assess the total number of patients initiated on PCSK9i 
along with a description of the clinical characteristics and 
lipid lowering treatment (LLT) of such patients.
setting A register-based descriptive cohort study of 
patients receiving a PCSK9i in the time period from 01 
January 2016 to 31 March 2017 using a cross linkage 
between three nationwide Danish registers. Information 
regarding PCSK9i prescriptions, patient demographics, 
concurrent pharmacotherapy, comorbidities and previous 
coronary procedures was identified.
results Overall, 137 patients initiated treatment with 
PCSK9i in the study period from 11 in the first quarter of 
2016 to 40 in the first quarter of 2017. The majority had 
a history of ischaemic heart disease (IHD) (67.9%) with 
ischaemic stroke and diabetes mellitus being present 
in 7.3% and 16.8% of patients, respectively. All patients 
initiated on PCSK9i had been previously prescribed 
statin treatment with atorvastatin and simvastatin being 
most frequently prescribed in 53% and 36% of patients, 
respectively. The majority of patients had received both 
statins and ezetimibe (94.9%) and approximately half of 
these patients had also received bile acid sequestrant 
(45.3%). Clinical characteristics mainly differed in patients 
receiving triple LLT compared with patients not receiving 
triple LLT in the regards of heart failure.
Conclusion Patients treated with PCSK9i were rare, 
characterised by having IHD and had received various 
and intensive conventional LLT prior to PCSK9i initiation in 
agreement with current international guidelines.
IntrOduCtIOn   
Atherosclerosis-related morbidity and 
mortality is reaching epidemic proportions 
worldwide and complications related to isch-
aemic heart disease (IHD) are the leading 
cause of death under 65 years of age.1 
Low-density lipoprotein cholesterol (LDL-C) 
is a well-established and modifiable constit-
uent in the pathogenesis of atherosclerosis 
and epidemiological studies have established 
LDL-C as one of the main risk factors for the 
development of atherosclerotic disease and 
IHD.1–3 
Since the late 1980s, statins have been used 
to lower LDL-C levels and reduce the risk of 
cardiovascular events and related mortality 
across the spectrum of primary and secondary 
prevention.4–6
Randomised trials have since targeted even 
lower LDL-C levels achieved by intensified 
strengths and limitations of this study
 ► In the present study, we utilised the Danish national 
registries to perform a description of the characteris-
tics of patients prescribed with PCSK9i on a national 
basis. We were able to include an unselected cohort 
of patients, with a great variety of comorbidities.
 ► The Danish nationwide registries include data on all 
residents regardless of participation in the labour 
market, and therefore is not affected by selection 
bias caused by including selected age groups, hos-
pitals or health insurance systems.
 ► Patients with familial hypercholesterolaemia (FH), 
who are also eligible for PCSK9i treatment, collect 
their PCSK9i at a specialised hospital unit and due to 
the design of the present study, we were not able to 
identify patients with a diagnosis with FH.
 ► Due to the observational registry design of the study, 
we were not able to retrieve data regarding bio-
chemical analyses, clinical arguments for initiation 
of PCSK9i, LLT after initiation of PCSK9i or adverse 
events with LLT.
 ► Due to a low diagnostic sensibility, we could not fully 
discriminate the indications for patients receiving 
PCSK9i.
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LDL-C lowering treatment (ie, higher dosage, more 
potent statins or additional ezetimibe) in patients with 
IHD, which has shown to further reduce the risk of 
cardiovascular disease (CVD).7–10
Novel treatment options to further lower the LDL-C 
levels are monoclonal antibodies to proprotein conver-
tase subtilisin-kexin type 9 (PCSK9), which have shown 
lowering of the LDL-C levels by 40%–60% and relative 
reduction of cardiovascular events by 15% (CI: 0.79–0.92) 
when added to background statin treatment.11
The European Society of Cardiology (ESC) and The American 
College of Cardiology (ACC) guidelines12 13 have endorsed 
PCSK9i treatment in patients at high risk and very high 
risk of future cardiovascular events. Partly due to the high 
cost of PCSK9i, most countries have established national 
guidelines and committees to approve a prior authorisa-
tion application for medicine subsidy in the individual 
patient. In Denmark, PCSK9i treatment were approved 
for medication subsidy in patients in very high risk of 
future CVD (ie, patients with a history of acute coronary 
syndrome, acute myocardial infarction, atherosclerotic 
polyvascular disease or diabetes mellitus with IHD) and 
in patients in high risk of future CVD (ie, patients with a 
history of stable angina pectoris or diabetes mellitus with 
either target organ damage, peripheral atherosclerotic 
artery disease, transitory cerebral ischaemia or ischaemic 
cerebral infarction) who despite maximally tolerated lipid 
lowering treatment (LLT) required further reduction 
of LDL-C levels. Established cut-off LDL-C values were 
3.0 mmol/L (115 mg/dL) and 3.5 mmol/L (135 mg/dL) 
in the very high-risk patients and high-risk patients, respec-
tively (online supplementary appendix figure 1). Statin 
intolerance in these patients would also be approved for 
subsidy when treatment with at least three types of statin 
starting in low dosages titrated to maximum tolerated 
dosage and ezetimibe and bile acid sequestrant had been 
attempted prior to PCSK9i initiation. The ESC and ACC 
guidelines further endorse additional clinical criteria (ie, 
patients with a history of isolated peripheral atheroscle-
rotic artery disease, isolated ischaemic cerebral infarction 
or diabetes mellitus with marked hypertension or hyper-
cholesterolaemia) and at different LDL-C measurement 
cut-off values. In these patients, however, there is a lack of 
treat to target trials and the effects of intensified LDL-C 
lowering is not with thorough evidence.14 15 Given the 
novelty of PCSK9i and the difference in national and 
international guidelines, we do not know the exact preva-
lence, the clinical characteristics, concurrent medication 
or the attempts of double and triple LLT in patients initi-
ated on PCSK9i.
In the present study, we wanted to assess the total 
number of patients initiated on PCSK9i in the first 
quarter (Q1) of 2016 to the Q1 of 2017 with a descrip-
tion of the clinical patient characteristics, comorbidi-
ties, medication use, concurrent LLT in these patients. 
Furthermore, we wanted to compare these parameters in 
patients attempted in triple LLT and patients in single or 
double LLT.
MethOds
In this register-based cohort study, information regarding 
patient demographics, comorbidities, coronary proce-
dures and concurrent medication use was identified using 
cross linkage between three different nationwide Danish 
registers. The Civil Registration System holds informa-
tion on date of birth, sex and survival status. The Danish 
National Patient Register holds information on every 
hospital admission in Denmark since 1978, in which each 
hospitalisation is registered at discharge with one primary 
diagnosis and, if applicable, one or more secondary 
diagnoses according to the International Classification 
of Diseases, the 10th revision (ICD-10) since 1994. The 
Danish National Patient Register also holds information 
on surgeries and procedures including percutaneous 
coronary intervention (PCI) and Coronary Artery Bypass 
Grafting (CABG). Comprising data on date, quantity, 
strength, formulation of all prescriptions dispensed from 
Danish pharmacies has been accurately registered in The 
Danish Registry of Medicinal Product Statistics since 1995 
and coded according to the Anatomical Therapeutic 
Chemical (ATC) classification system.
All Danish patients with a prescription for PCSK9i (ATC 
code C10A×13 or C10A×14) between 1 January 2016 and 
31 March 2017 were included in the study cohort on the 
day they redeemed their prescription. Since 1 March 
2017, PCSK9i were collected at specialised units at Danish 
hospitals and prescriptions of PCSK9i in the time period 
from 1 March 2017 to 31 March 2017 were not registered 
in the present study.
Demographic information on age, sex and vital status 
was identified using The Civil Registration System. Comor-
bidities and coronary procedures were identified using 
The Danish National Patient Register. Information on 
diabetes mellitus and hypertension was identified using 
The Danish Registry of Medicinal Product Statistics along 
with the concurrent medication (online supplementary 
appendix table 1).
statistics
Categorical data is presented as counts with percent-
ages. Statistical difference was tested using chi-squared 
test or Fisher's exact test where appropriate. Continuous 
variables were reported as medians with IQR. Statistical 
difference was tested using the Wilcoxon rank-sum test. A 
p value <0.05 was considered significant.
Data management and statistical analyses were 
conducted using R statistics, V.3.4.3 (R Core Team [2017]. 
R: A language and environment for statistical computing. 
R Foundation for Statistical Computing, Vienna, Austria. 
URL http://www. R- project. org/).
ethics
In Denmark, retrospective register studies do not 
require approval from the ethics committees. The 
ethical legislation in Denmark does not permit the 
reporting of clinical patient characteristics in less 
than three patients. Data were made available in an 
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anonymised format such that specific individuals could 
not be identified. The Danish Data Protection Agency 
approved this study (ref. no.: 2007-58-0015/GEH-2014-
016 I-Suite no.: 02734) 
Patient and public involvement
Patients and public were not involved in this research 
project.
results
The total number of patients treated with PCSK9i during 
the total study period of 15 months was 137. The total 
number of patents initiating PCSK9i increased from 11 
in Q1 of 2016 to 40 in Q1 of 2017 (figure 1). The overall 
median age was 62 (IQR: 55–68) years and 53.3% were 
men with no difference in number of men and women 
initiated (online supplementary appendix figure 2). The 
majority of patients had a history of IHD (68%) with 
51.1% having received PCI and 24.8% having received 
CABG. All patients had filled a prescription of statin 
(100%) prior to initiation of PCSK9i with atorvastatin and 
simvastatin being most frequently prescribed in 57.7% 
and 32.1% of patients, respectively (table 1).
The majority of patients had received statins in 
dosages of 80 mg (43.8%) or 40 mg (46.7%). Of the 
137 included patients, 94.9% of patients had filled 
a prescription of ezetimibe in addition to statin and 
43.1% of patients had filled a prescription of three 
types of LLT with bile acid sequestrants and ezetimibe 
in addition to statin. Few patients had filled a prescrip-
tion of statin alone (2.9%) and 50% of all patients had 
filled a prescription of either fibrates or nicotinic acid 
(figure 2 and table 1).
Patients in dual LLT were more prone to have heart-
failure than patients attempted in triple LLT prior to 
PCSK9i initiation. No other statistical difference regarding 
demographics, diseases, concurrent medication or coro-
nary procedures was found between the patients receiving 
triple therapy compared with the patients not receiving 
triple LLT (table 2).
Figure 1 Bar plot illustrating the number of patients initiated 
with PCSK9 inhibitor treatment by calendar quarter. Q1 
2016=01 January 2016–31 March 2016; Q2 2016=01 April 
2016–30 June 2016; Q3 2016=01 July 2016–30 September 
2016; Q4 2016=01 October 2016–31December 2016; Q1 
2017=01 January 2017–31 March 2017.
Table 1 Clinical characteristics, demographics and 
medication use of patients initiated on PCSK9 inhibitors
Parameter Study cohort
Number of patients, n 137
Age (median (IQR)) 62 (55–68)
Men, n (%) 73 (53.3)
Ischaemic stroke, n (%) 10 (7.3)
Ischaemic heart disease, n (%) 93 (68)
Peripheral artery disease, n (%) 4 (3)
Chronic obstructive pulmonary disease, n (%) 5 (3.6)
Heart failure, n (%) 13 (9.5)
Chronic kidney disease, n (%) 11 (8.0)
Hypertension, n (%) 62 (45.3)
Diabetes, n (%) 23 (16.8)
Non-loop diuretics, n (%) 38 (27.7)
Loop diuretics, n (%) 22 (16.1)
Beta blockers, n (%) 61 (44.5)
Calcium channel blockers, n (%) 29 (21.2)
RAS-inhibitors, n (%) 50 (36.5)
Acetyl salicylic acid, n (%) 76 (55.5)
NSAID, n (%) 19 (13.9)
ADP-inhibitors, n (%) 38 (27.7)
Statin use, n (%) 137 (100.0)
Dosage of statins (%)
  20 mg 13 (9.5)
  40 mg 64 (46.7)
  80 mg 60 (43.8)
Type of statin, n (%)
  Atorvastatin 72 (52.6)
  Fluvastatin 4 (2.9)
  Pravastatin 5 (3.6)
  Rosuvastatin 7 (5.1)
  Simvastatin 49 (35.8)
Fibrates, n (%) 30 (21.9)
Bile acid sequestrant, n (%) 62 (45.3)
Nicotine acid, n (%) 39 (28.5)
Ezetimibe, n (%) 130 (94.9)
PCI, n (%) 70 (51.1)
CABG, n (%) 34 (24.8)
ADP-inhibitors, adenosine diphosphate inhibitors; CABG, 
coronary artery bypass graft; NSAID, non-steroidal anti-
inflammatory drugs; PCI, percutaneous coronary intervention; 
PCSK9 inhibitors, proprotein convertase subtilisin-kexin type 9 
inhibitors; RAS-inhibitors, renin-angiotensin system inhibitors.
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dIsCussIOn
In this nationwide study, we described the prevalence and 
clinical and demographical characteristics of patients 
treated with PCSK9i over a 1-year period from 2016 to 
2017. PCSK9i were prescribed in a total of 137 patients 
with an increase from 11 initiated patients in the Q1 of 
2016 to 40 initiated patients in the Q1 of 2017. Patients 
were characterised by having a history of IHD and having 
received PCI and CABG. PCSK9i initiation was consis-
tently clustered in patients attempted to reach maximum 
tolerated LLT resembled by various types and dosages of 
statins and patients having attempted dual LLT and half 
having attempted triple LLT. Patients in dual LLT were 
more prone to have  heart failure than patients attempted 
in triple LLT prior to PCSK9i initiation.
We found three similar studies describing the clinical 
characteristics and LLT prior to PCSK9i initiation.16–18 In 
Rane et al and Mues et al, only 54% and 19% of patients 
had received two types of LLT, 24% and 26% of patients 
did not receive any LLT prior to initiation with PCSK9i, 
respectively and only 17% of patients had previously 
received three types of LLT. Also, in Fairman et al and 
Rane et al, 60% and 69% of patients, respectively, were in 
treatment with statin as monotherapy. The results from 
these studies are in discrepancy with the present study 
where 100% of patients had received statin treatment, 
97% had received minimum two types of LLT and only 
3% were in statin treatment alone. Physician reported 
intolerability to statin in 32% of the patients initiated on 
PCSK9i greatly influenced PCSK9i initiation in Rane et al. 
However, ezetimibe was attempted surprisingly infrequent 
(7.6% of patients) in contrast to the present study where 
ezetimibe was prescribed in 94.9% of patients. Differences 
of eligibility of PCSK9i in the ESC guidelines compared 
with the ACC guidelines could possibly also have influ-
enced treatment regimens with LLT prior to PCSK9i initi-
ation.12 19–21 We observed a more rigorous adherence in 
attempting statin treatment and additional conventional 
non-statin treatment prior to initiation of PCSK9i in the 
present study compared with similar studies and studies 
of patients at high risk of CVD not receiving PCSK9i.22–24 
Figure 2 Venn diagram illustrating combinations of 
prescribed lipid lowering treatment in 137 patients initiated 
on PCSK9 inhibitors.
Table 2 Clinical characteristics, demographics and 
medication use by number of lipid lowering drugs prescribed 
(not triple therapy vs triple therapy) prior to initiation of 
PCSK9 inhibitors
Parameter
Not triple 
treatment
Triple 
treatment
Number of patients, n 78 59
Age, median (IQR) 61 (55–68) 62 (56–69)
Men, n (%) 42 (53.8) 31 (52.5)
Ischaemic stroke, n (%) 6 (7.7) 4 (6.8)
Ischaemic heart disease, n (%) 54 (69.2) 39 (66.1)
Chronic obstructive pulmonary 
disease, n (%)
4 (5.1) <3 (<5%)
Heart failure, n (%) 10 (12.8) 3 (5.1)
Chronic kidney disease, n (%) 6 (7.7) 5 (8.5)
Hypertension, n (%) 34 (43.6) 28 (47.5)
Diabetes, n (%) 14 (17.9) 9 (15.3)
Non-loop diuretics, n (%) 20 (25.6) 18 (30.5)
Loop diuretics, n (%) 16 (20.5) 6 (10.2)
Beta blockers, n (%) 30 (38.5) 31 (52.5)
Calcium channel blockers, n (%) 17 (21.8) 15 (25.4)
RAS-inhibitors, n (%) 28 (35.9) 22 (37.3)
Acetyl salicylic acid, n (%) 48 (61.5) 28 (47.5)
NSAID, n (%) 12 (15.4) 7 (11.9)
ADP-inhibitors, n (%) 17 (21.8) 21 (35.6)
Dosage of statins (%)
  20 mg 6 (7.7) 7 (11.9)
  40 mg 40 (51.3) 24 (40.7)
  80 mg 32 (41.0) 28 (47.5)
Type of statin, n (%)
  Atorvastatin 46 (59.0) 33 (55.9)
  Fluvastatin <3 (<4%) <3 (<5%)
  Pravastatin <3 (<4%) 4 (6.8)
  Rosuvastatin 5 (6.4) <3 (<5%)
  Simvastatin 26 (33.3) 18 (30.5)
Fibrates, n (%) 14 (17.9) 16 (27.1)
Nicotine acid, n (%) 20 (25.6) 19 (32.2)
PCI, n (%) 38 (48.7) 32 (54.2)
CABG, n (%) 22 (28.2) 12 (20.3)
ADP, adenosine diphosphate; CABG, coronary artery bypass graft; 
NSAID, non-steroidal anti-inflammatory drugs; PCI, percutaneous 
coronary intervention; RAS, renin-angiotensin system. 
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The infrequent use of rosuvastatin was primarily due 
to a protecting marketing patent, making rosuvastatin 
more expensive than atorvastatin making atorvastatin the 
first choice of potent statin in Denmark. Simvastatin is 
primarily used in the process of overcoming side effects 
of potent statin treatment in patients with IHD in order 
to reach maximum tolerated dose of LLT or as primary 
prophylaxis treatment of CVD. In our cohort, 36% of 
patients received simvastatin, which most likely indicates 
attempts of titrating to maximum tolerated dosage of 
statin when considering the strict national criteria for 
medicine subsidy regarding PCSK9i treatment and most 
patients had IHD. This could indicate persistent attempts 
of reaching LDL-C target goals in adherence to national 
clinical guidelines, and a last resort usage of PCSK9i.
We found that patients in dual LLT were more prone to 
have heart failure than patients attempted in triple LLT 
prior to PCSK9i initiation. The treating physician could 
possibly be susceptible to more intensive lowering of 
LDL-C to reduce the risk of future cardiovascular events 
in the more frail patients such as patients with verified 
heart failure. Although patients were initiated according 
to both national and international guidelines, perhaps 
certain other clinical traits might influence both physi-
cians and committee's approving of medicine subsidy for 
PCSK9i.25 Patients' demographics and concurrent medi-
cation use did notsignificantly differ in patients having 
received triple LLT and patients not having received 
triple LLT.
Despite having been endorsed by guidelines for 
patients with many different kinds of atherosclerotic 
CVD, 66% of the patients initiated on PCSK9i had a 
history of IHD (online supplementary appendix figure 
2). The large randomised trials investigating the effects 
of intensified LLT7 9 10 26–29 or PCSK9i treatment11 30–37 
on reducing future cardiovascular events have predomi-
nately included patients with established IHD or a recent 
IHD related event. The Danish national guidelines have 
also adapted more accommodative criteria for PCKS9i 
initiation in patients with a history of IHD, which explains 
the clustering of PCSK9i in such patients. Repeating our 
research in another country might show different results 
regarding the clinical patient characteristics, which prob-
ably will become more streamlined along with the publi-
cation of long-term randomised trials evaluating PCSK9i 
treatment.
Even though we observed an increasing number of 
patients initiated on PCSK9i, only 137 patients in total 
were prescribed with PCSK9i over the study period. Statins 
are the first-line treatment, more frequently used and 
have established effectiveness on improving long-term 
cardiovascular outcomes in both primary and secondary 
prevention trials without being extensively expensive 
compared with PCSK9i.
PCSK9i are without established long-term effectiveness 
on major cardiovascular events and clinical trials are still 
ongoing. Based on the current evidence of the effective-
ness of PCSK9i on reducing major cardiovascular events, 
the Institute for Clinical and Economic Review (ICER) 
reported a number needed to treat for 5 years to avoid 
one major cardiovascular event (NNT5) of 28 individ-
uals.38 While randomised clinical trials of PCSK9i have 
shown beneficial efficacy, they are very expensive and this 
may have had major influence on theoverall clinical 
implementation. The cost ofPCSK9i is around $14 350 
per year in 2017, generating a cost-effectiveness ratio 
which may exceed a threshold of price pr. quality-affected 
life years. These economic considerations together with 
a possible postponed apprising of PCSK9i as a treatment 
option may explain why PCSK9i have been used rather 
infrequent when also taking into account how many 
patients who actually need further LLT.39 40 Economic 
considerations can also help explain the modified and 
individually formed national guidelines for PCSK9i initi-
ation. Committing fully to the criteria for PCSK9i initia-
tion stated in the ESC or ACC guidelines would probably 
not be realistic for any countries’ medical expenditures, 
resulting in many patients being rejected for medicine 
subsidy and patients with certain clinical characteris-
tics being favored25. Ongoing trials will help establish 
whether further lowering of LDL-C has sufficient bene-
ficial effects to implement PCSK9i on a wider scale and 
whether the cost-effectiveness of such implementation is 
favourable. In conclusion, conventional LLT had its core 
role in a first line of treatment to provide an initial assess-
ment of LDL-C lowering by using various types of statin 
in various dosages with frequent attempts of double and 
triple LLT prior to PCSK9i initiation in patients in high 
or very high  risk of CVD. The main usage of PCSK9i were 
in patients predominately with IHD in treatment with 
statin and ezetemibe in agreement with current national 
and international clinical guidelines. 
strengths and limitations of this study
In the present study, we utilised the Danish national 
registries to perform a description of the characteristics 
of patients prescribed with PCSK9i on a national basis. 
We were able to include an unselected cohort of patients, 
with a great variety of comorbidities. The Danish nation-
wide registries include data on all residents regardless of 
participation in the labour market and therefore are not 
affected by selection bias caused by including selected age 
groups, hospitals or health insurance systems.
Patients with familial hypercholesterolaemia (FH), 
who are also eligible for PCSK9i treatment, collect their 
PCSK9i at a specialised hospital unit and due to the design 
of the present study, we were not able to identify patients 
with a diagnosis of FH.
Due to the observational design of the present study, we 
were not able to retrieve data regarding biochemical anal-
yses, clinical reasons for initiation of PCSK9i, LLT after 
initiation of PCSK9i or adverse events with statin treat-
ment. Both statin and non-statin treatment in different 
dosages were applied in almost every patient in the present 
study, which may reflect clinical decisions of resolving 
intolerable adverse effects, reaching LDL-C target levels 
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or strict adherence to guidelines. Due to a low diagnostic 
sensibility, we were not able to fully discriminate the indi-
cations of patients receiving PCSK9i.
We did not include a comparative cohort of patients 
not receiving PCSK9i; however, we were able to compare 
clinical characteristics, comorbidities and demographics 
in the present study with an observational study investi-
gating CVD and LLT in the Danish general population.39
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